NEW YORK (GenomeWeb News) - UK cancer detection firm Oncimmune will develop a diagnostic test for lung cancer using Proteome Sciences’ patents covering the Annexin I and Annexin 2 proteins under a non-exclusive licensing agreement announced by the two firms this week.
A test is expected to hit the market during the first half of the year, Proteome Sciences said in a statement. It will receive royalty payments from product sales under the agreement.
Further terms of the deal were not disclosed.
Proteome Sciences received US patent number 6,645,465 covering the Annexin proteins and antibodies in late 2003. The proteins have a putative role in controlling cell signaling and metabolism and have been associated with various diseases.
The company also said this week that it has increased the plexing rates for its TMT isobaric mass tags. Currently available in single, two-, and six-plex, it will become available in 12- and 18-plex some time this year, Proteome Sciences said.
The TMT technology, which is offered by Thermo Fisher Scientific under a licensing agreement, pertains to a method for labeling analytes in multiplex fashion in a mass spectrometer.